1
|
Zhao W, Zhao J, Zhang Z, Han T, Wang J, Zhou X. Evaluating early-stage disk halo changes after small incision lenticule extraction. Eur J Ophthalmol 2022; 33:11206721221138306. [PMID: 36377271 DOI: 10.1177/11206721221138306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2024]
Abstract
PURPOSE To investigate early changes in the disk halo under different light conditions after myopic small incision lenticule extraction (SMILE). METHODS This prospective study included 70 eyes of 70 myopic patients aged 18-33 years, with a spherical equivalent (SE) of -5.87 ± 1.86 D, who underwent SMILE. The subjective refraction, higher-order aberrations (HOAs), pupillometry, and halo were measured preoperatively and postoperatively to analyse disk halo variations and correlated factors. RESULTS At 5 cd/m2 and 1 cd/m2 luminance, the halo radius in the high myopia (HM) group reached a postoperative peak after 1 week (p = 0.000 and 0.019, respectively), and recovered to baseline after 3 months. In the low-to-moderate (LM) myopia group, the halo radius did not differ 1 week postoperatively compared to the preoperative level (p = 0.015), but significantly improved after 3 months (p = 0.000). The halo radius correlated with SE, uncorrected distance visual acuity (UDVA), ocular HOAs, coma, and the pupillary light reflex in the LM group at all time points, but there were no correlations in the HM group. CONCLUSIONS Halo symptoms occurred early after SMILE, but recovered within 3 months. The recovery process was slower in the HM group than in the LM group, and the halo radius correlated with SE, UDVA, ocular HOAs, coma, and the pupillary light reflex.
Collapse
Affiliation(s)
- Wuxiao Zhao
- Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China
- NHC Key Laboratory of Myopia (Fudan University), Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, China
- Shanghai Research Center of Ophthalmology and Optometry, Shanghai, China
- Shanghai Engineering Research Center of Laser and Autostereoscopic 3D for Vision Care (20DZ2255000), Shanghai, China
- Present at Center for Optometry and Visual Science, Guangxi Academy of Medical Sciences, Nanning, China
| | - Jing Zhao
- Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China
- NHC Key Laboratory of Myopia (Fudan University), Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, China
- Shanghai Research Center of Ophthalmology and Optometry, Shanghai, China
- Shanghai Engineering Research Center of Laser and Autostereoscopic 3D for Vision Care (20DZ2255000), Shanghai, China
| | - Zhe Zhang
- Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China
- NHC Key Laboratory of Myopia (Fudan University), Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, China
- Shanghai Research Center of Ophthalmology and Optometry, Shanghai, China
- Shanghai Engineering Research Center of Laser and Autostereoscopic 3D for Vision Care (20DZ2255000), Shanghai, China
| | - Tian Han
- Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China
- NHC Key Laboratory of Myopia (Fudan University), Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, China
- Shanghai Research Center of Ophthalmology and Optometry, Shanghai, China
- Shanghai Engineering Research Center of Laser and Autostereoscopic 3D for Vision Care (20DZ2255000), Shanghai, China
| | - Jifang Wang
- Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China
- NHC Key Laboratory of Myopia (Fudan University), Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, China
- Shanghai Research Center of Ophthalmology and Optometry, Shanghai, China
- Shanghai Engineering Research Center of Laser and Autostereoscopic 3D for Vision Care (20DZ2255000), Shanghai, China
| | - Xingtao Zhou
- Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China
- NHC Key Laboratory of Myopia (Fudan University), Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, China
- Shanghai Research Center of Ophthalmology and Optometry, Shanghai, China
- Shanghai Engineering Research Center of Laser and Autostereoscopic 3D for Vision Care (20DZ2255000), Shanghai, China
| |
Collapse
|
2
|
Pepose J, Brigell M, Lazar E, Heisel C, Yousif J, Rahmani K, Kolli A, Hwang M, Mitrano C, Lazar A, Charizanis K, Sooch M, McDonald M. A randomized phase 2 clinical trial of phentolamine mesylate eye drops in patients with severe night vision disturbances. BMC Ophthalmol 2022; 22:402. [PMID: 36209072 PMCID: PMC9548101 DOI: 10.1186/s12886-022-02621-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Accepted: 09/26/2022] [Indexed: 11/10/2022] Open
Abstract
PURPOSE Dim light vision disturbances (DLD) comprise a wide range of symptoms affecting the quality of vision at low illumination including glare, halos, and starbursts. This exploratory study investigated 1.0% phentolamine mesylate ophthalmic solution (PMOS) as a treatment to improve vision and image quality for patients with DLD. METHODS In this placebo-controlled, randomized, double-masked clinical trial, 24 adult patients with severe DLD were randomized in a 2:1 ratio to receive either one dose of PMOS or placebo. Subjects were eligible if they reported experiencing severe night vision difficulty that was not eliminated by distance spectacle correction and scored ≥0.3 log units below the normal range of contrast sensitivity assessed under mesopic conditions with glare at ≥2 spatial frequencies. Key efficacy outcomes were change from baseline in pupil diameter, contrast sensitivity, and visual acuity. Safety measures including intraocular pressure, conjunctival hyperemia, and systemic effects were also assessed. RESULTS Eight subjects were randomized to placebo (63% female; mean age 47 years) and 16 were randomized to PMOS (75% female; mean age 42 years). Mean (SD) pupil diameter of PMOS-treated subjects decreased significantly - 1.3 mm (0 to - 2.8 mm) with p < 0.0001. Mean contrast sensitivity with glare in PMOS-treated subjects improved significantly post-treatment at spatial frequencies 3, 6, 12, and 18 cycles per degree (p ≤ 0.03). PMOS also demonstrated improvements in the numbers of letters read for mesopic and photopic, high- and low-contrast visual acuity (LCVA). Importantly, a statistically greater proportion of PMOS-treated eyes registered mesopic LCVA 5 letter (69% vs. 31%, p = 0.029) and 10 letter (34% vs. 6%, p = 0.04) improvement, with a trend at 15 letters (19% vs. 0%, p = 0.16). PMOS was well tolerated with the only reported side effect being a mild increase in conjunctival hyperemia. CONCLUSION PMOS was well tolerated and effectively reduced pupil size with improvements in contrast sensitivity and visual acuity in adults with severe DLD. Future Phase 3 studies should be conducted to further evaluate its potential to treat DLD. TRIAL REGISTRATION The trial registration number is NCT04004507 (02/07/2019). Retrospectively registered.
Collapse
Affiliation(s)
- Jay Pepose
- Pepose Vision Institute, St. Louis, MO, USA.,Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, MO, USA
| | - Mitchell Brigell
- Ocuphire Pharma, Inc., 37000 Grand River Ave., Suite 120, Farmington Hills, MI, 48335, USA
| | | | - Curtis Heisel
- Ocuphire Pharma, Inc., 37000 Grand River Ave., Suite 120, Farmington Hills, MI, 48335, USA
| | - Jonah Yousif
- Ocuphire Pharma, Inc., 37000 Grand River Ave., Suite 120, Farmington Hills, MI, 48335, USA
| | - Kavon Rahmani
- Ocuphire Pharma, Inc., 37000 Grand River Ave., Suite 120, Farmington Hills, MI, 48335, USA.
| | - Ajay Kolli
- Ocuphire Pharma, Inc., 37000 Grand River Ave., Suite 120, Farmington Hills, MI, 48335, USA
| | - Min Hwang
- Ocuphire Pharma, Inc., 37000 Grand River Ave., Suite 120, Farmington Hills, MI, 48335, USA
| | - Cara Mitrano
- Ocuphire Pharma, Inc., 37000 Grand River Ave., Suite 120, Farmington Hills, MI, 48335, USA
| | - Audrey Lazar
- Ocuphire Pharma, Inc., 37000 Grand River Ave., Suite 120, Farmington Hills, MI, 48335, USA
| | | | - Mina Sooch
- Ocuphire Pharma, Inc., 37000 Grand River Ave., Suite 120, Farmington Hills, MI, 48335, USA
| | - Marguerite McDonald
- Department of Ophthalmology, New York University Langone Medical Center, New York, NY, USA
| |
Collapse
|
3
|
Effect of over-the-counter brimonidine tartrate 0.025% ophthalmic solution on pupil size in healthy adults. Graefes Arch Clin Exp Ophthalmol 2021; 259:3333-3338. [PMID: 34251483 PMCID: PMC8523379 DOI: 10.1007/s00417-021-05297-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2021] [Revised: 06/09/2021] [Accepted: 06/24/2021] [Indexed: 11/09/2022] Open
Abstract
Purpose To evaluate the effect of brimonidine tartrate 0.025% ophthalmic solution on pupil size under scotopic conditions in healthy adults Methods Pupil size was measured in 56 eyes of 28 volunteer participants using a pupillometer under scotopic conditions. Age, gender, and iris color were recorded. Subjects using any ophthalmic medications other than artificial tears were excluded. The pupil size was subsequently measured again under scotopic conditions 60 min after instillation of brimonidine tartrate 0.025% ophthalmic solution. Results Statistically significant miosis was seen after instillation of brimonidine tartrate 0.025% (p = 0.04). Average pupil size prior to brimonidine 0.025% instillation was 7.28 ± 1.05 mm, and average pupil size after instillation of brimonidine 0.025% was 6.36 ± 1.68 mm, a reduction of − 23.7% in pupil area. Subjects with light irides demonstrated a greater miotic effect than subjects with dark irides (1.55 mm vs. 0.67 mm, p < 0.0001), with a pupil area reduction of − 37.6% and − 17.4%, respectively. The amount of miosis was independent of initial pupil size. Conclusions Brimonidine tartrate 0.025% causes significant miosis in scotopic settings, although the effect is not as great in darker colored eyes. Further studies are needed to determine the latency and duration of the effect and whether the amount of miosis is clinically significant.
Collapse
|
4
|
Foster GJL, Ayres B, Fram N, Khandewal S, Ogawa GSH, MacDonald SM, Miller KM, Snyder ME, Vasavada AR. Management of common iatrogenic iris defects induced by cataract surgery. J Cataract Refract Surg 2021; 47:522-532. [PMID: 32925648 DOI: 10.1097/j.jcrs.0000000000000411] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2020] [Accepted: 07/18/2020] [Indexed: 11/26/2022]
Abstract
The proximity of the iris to the instruments and currents of cataract surgery makes iatrogenic damage to the iris a common complication of cataract surgery. This article discusses techniques to prevent or minimize this damage. When damage does occur, the surgeon must decide if, when, and how to repair the damage. Principles governing these decisions and techniques for repair are discussed. Figures and videos, included as online Supplemental Data files, illustrate cases of iatrogenic damage and repair techniques.
Collapse
Affiliation(s)
- Gary J L Foster
- From The Eye Center of Northern Colorado, PC (Foster), Fort Collins, Colorado, Ophthalmic Partners of PA (Ayres), Bala Cynwyd, Pennsylvania, Advanced Eye Care (Fram), Los Angeles, California, Baylor College of Medicine (Khandelwal), Houston, Texas, Eye Corps (MacDonald), Dallas, Texas, Tufts University School of Medicine (MacDonald), Boston, Massachusetts, Stein Eye Institute (Miller), University of California, Los Angeles, Los Angeles, California, Eye Associates of New Mexico, University of New Mexico (Ogawa), Albuquerque, New Mexico, Cincinnati Eye Institute (Snyder), Cincinnati, Ohio, USA; Iladevi Cataract & IOL Research Center (Vasavada) Ahmedabad, India
| | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Kato COS, Shimizu K, Kamiya K, Ishikawa H, Igarashi A. Effects of brimonidine tartrate 0.1% ophthalmic solution on the pupil, refraction, and light reflex. Sci Rep 2018; 8:9003. [PMID: 29899357 PMCID: PMC5998017 DOI: 10.1038/s41598-018-27436-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2017] [Accepted: 05/29/2018] [Indexed: 01/07/2023] Open
Abstract
This study aimed to assess changes in pupil size, uncorrected visual acuity, refraction, and the direct and consensual light reflexes after instillation of brimonidine 0.1% in healthy subjects. The investigation comprised 46 eyes of 23 healthy subjects with no eye diseases in whom brimonidine 0.1% was instilled in the right eye. Pupil size was measured quantitatively under photopic and scotopic conditions, uncorrected visual acuity, refraction, and direct and consensual light reflexes before and at 1, 6, and 24 h after instillation. We found No significant change was found in refraction or uncorrected visual acuity (P = 0.999 and P = 0.998, respectively). A significant reduction in pupil size was observed under scotopic conditions at 1 h and 6 h after instillation (P = 0.007 and P = 0.005, respectively). The rate of pupil contraction and constriction speed measured by light reflexes were significantly increased at 1 h and 6 h after instillation (P = 0.021 and P = 0.033, respectively). Brimonidine 0.1% induced a significant reduction in pupil size under scotopic conditions without a significant change in refraction or visual acuity due to suppression of the sympathetic nervous system.
Collapse
Affiliation(s)
| | | | - Kazutaka Kamiya
- 0000 0000 9206 2938grid.410786.cDepartment of Ophthalmology, University of Kitasato School of Medicine, Kanagawa, Japan
| | - Hitoshi Ishikawa
- 0000 0000 9206 2938grid.410786.cDepartment of Ophthalmology, University of Kitasato School of Medicine, Kanagawa, Japan
| | | |
Collapse
|
6
|
Jiménez JR, Alarcón A, Anera RG, Jiménez Del Barco L. Q-optimized Algorithms: Theoretical Analysis of Factors Influencing Visual Quality After Myopic Corneal Refractive Surgery. J Refract Surg 2017; 32:612-7. [PMID: 27598731 DOI: 10.3928/1081597x-20160531-01] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2015] [Accepted: 05/03/2016] [Indexed: 11/20/2022]
Abstract
PURPOSE To model the effect of pupil size, optical zone, and initial myopic level on the retinal image quality after Q-optimized myopic corneal refractive surgery. METHODS Different Q-optimized and paraxial Munnerlyn algorithms were tested using a schematic myopic eye model to analyze the optical quality of the final retinal image for initial myopic errors from -1.00 to -7.00 diopters (D). Different optical zones (5.5, 6, and 6.5 mm in diameter) and two pupil diameters (5 and 7 mm, mesopic-scotopic conditions) were included in the comparison. Modulation transfer function (MTF) and area under the MTF from 0 to 60 cycles per degree (MTFa) were calculated by ray tracing to evaluate this retinal image quality. RESULTS The Q-optimized algorithm with Q = -0.45 provided the highest MTF and MTFa results for myopic corrections less than -5.00 D. For refractive errors greater than -5.00 D, Q = -0.26 provided the highest MTF and MTFa results. CONCLUSIONS Q-optimized algorithms improve the visual outcomes with respect to the paraxial Munnerlyn algorithm for myopic corneal surgery. The results show that the Q value that optimizes the results of the Q-optimized algorithm depends on the degree of myopia to correct and the size of the pupil. [J Refract Surg. 2016;32(9):612-617.].
Collapse
|
7
|
Abdelkader A, Kaufman HE. Clinical outcomes of combined versus separate carbachol and brimonidine drops in correcting presbyopia. EYE AND VISION 2016; 3:31. [PMID: 27981057 PMCID: PMC5139101 DOI: 10.1186/s40662-016-0065-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/14/2016] [Accepted: 11/24/2016] [Indexed: 11/30/2022]
Abstract
Background To test and compare in a masked fashion the efficacy of using a parasympathomimetic drug (3% carbachol) and an alpha-2 agonist (0.2% brimonidine) in both combined and separate forms to create optically beneficial miosis to pharmacologically improve vision in presbyopia. Methods A prospective, double-masked, randomized, controlled clinical trial was conducted. Ten naturally emmetropic and presbyopic subjects between 42 and 58 years old with uncorrected distance visual acuity of at least 20/20 in both eyes without additional ocular pathology were eligible for inclusion. All subjects received 3% carbachol and 0.2% brimonidine in both combined and separate forms, 3% carbachol alone and 0.2% brimonidine (control) alone in their non-dominant eye in a crossover manner with one week washout between tests. The subjects’ pupil sizes and both near and distance visual acuities will be evaluated pre- and post-treatment at 1, 2, 4, and 8 h, by a masked examiner at the same room illumination. Results Statistically significant improvement in mean near visual acuity (NVA) was achieved in all subjects who received combined 3% carbachol and 0.2% brimonidine in the same formula compared with those who received separate forms or carbachol alone or brimonidine alone (P < 0.0001). Conclusion Based on the data, the combined solution demonstrated greater efficacy than the other solutions that were tested. Improving the depth of focus by making the pupil small caused statistically significant improvement in near visual acuity, with no change in binocular distance vision. Trial registration ACTRN12616001565437. Registered 11 November 2016.
Collapse
Affiliation(s)
- Almamoun Abdelkader
- Department of Ophthalmology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
| | - Herbert E Kaufman
- Department of Ophthalmology, Louisiana State University Eye Center, LSU Medical School, New Orleans, LA USA
| |
Collapse
|
8
|
Tatsui S, Ishikawa H, Shimizu K, Mashimo K. Pre- and postsynaptic effects of brimonidine on isolated rabbit iris dilator muscles. Clin Ophthalmol 2016; 10:845-9. [PMID: 27274189 PMCID: PMC4869645 DOI: 10.2147/opth.s100755] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Purpose Brimonidine is an imidazoline compound used for the treatment of glaucoma, but having very little effect on pupil diameter. Like para-aminoclonidine, most imidazoline compounds interact with postsynaptic α-adrenoceptors and cause pupil dilatation. Therefore, as part of an investigation of the mechanism of action of brimonidine on pupil diameter, the present study was initiated to measure, in vitro, the relative potency of brimonidine on the pre- and postsynaptic α-adrenoceptors of rabbit iris dilator muscle. Methods The contractile activity of brimonidine and its effect on twitch contraction evoked by electrical field stimulation were studied in isolated rabbit iris dilator muscles by isometric tension recording. Results Brimonidine significantly inhibited the twitch contraction of the dilator muscle caused by field stimulation, without affecting the response to exogenously applied phenylephrine. Compared to phenylephrine, brimonidine caused only a small contractile response with % maximum contraction values of <10%. Conclusion These results suggest that brimonidine may act on nerve endings to inhibit adrenergic neurotransmission with very little effect on postsynaptic α-adrenoceptors. This may indicate that brimonidine reduced the pupil diameter just a little, thus improving night vision.
Collapse
Affiliation(s)
- Sonoko Tatsui
- Department of Ophthalmology, School of Medicine, Kitasato University, Sagamihara, Japan
| | - Hitoshi Ishikawa
- Department of Orthoptics and Visual Sciences, School of Allied Health Sciences, Kitasato University, Sagamihara, Japan
| | - Kimiya Shimizu
- Department of Ophthalmology, School of Medicine, Kitasato University, Sagamihara, Japan
| | - Kimiyo Mashimo
- Department of Ophthalmology, School of Medicine, Kitasato University, Sagamihara, Japan
| |
Collapse
|
9
|
Schallhorn S, Brown M, Venter J, Hettinger K, Hannan S. The Role of the Mesopic Pupil on Patient-Reported Outcomes in Young Patients With Myopia 1 Month After Wavefront-Guided LASIK. J Refract Surg 2014; 30:159-65. [DOI: 10.3928/1081597x-20140217-02] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2013] [Accepted: 11/20/2013] [Indexed: 11/20/2022]
|
10
|
Alarcón A, Rubiño M, Pééérez-Ocón F, Jiménez JR. Theoretical analysis of the effect of pupil size, initial myopic level, and optical zone on quality of vision after corneal refractive surgery. J Refract Surg 2013; 28:901-6. [PMID: 23310967 DOI: 10.3928/1081597x-20121106-01] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
PURPOSE To analyze the theoretical effect that pupil size, optical zone, and initial myopic level have on the final retinal image after corneal refractive surgery. METHODS A schematic myopic eye model corrected by the Munnerlyn formula was used to analyze the optical quality of the final retinal image. Root-mean-square radius spot and modulation transfer function were cal- culated by ray tracing to evaluate retinal image quality. RESULTS Pupil size had a negative effect on the retinal image only when it was greater than the diameter of the optical zone. In addition, the greater the initial myopic level, the more the pupil size affected image quality. Thus, a clear dependence exists between the initial myopic level and effect that the pupil size can have on the retinal image after laser refractive surgery. CONCLUSIONS Pupil size may be a risk factor for night vision disturbances, but only when it is larger than the theoretical optical zones utilized in this study. Its effect depends not only on the optical zone size, but also on the initial "myopic level. Therefore, this relationship should be taken into account during patient selection for refractive surgery
Collapse
Affiliation(s)
- Aixa Alarcón
- Laboratory of Vision Sciences and Applications, University of Granada, Spain.
| | | | | | | |
Collapse
|
11
|
Effect of brimonidine tartrate 0.10% ophthalmic solution on pupil diameter. J Cataract Refract Surg 2011; 37:486-9. [DOI: 10.1016/j.jcrs.2010.09.026] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2010] [Revised: 09/15/2010] [Accepted: 09/16/2010] [Indexed: 11/24/2022]
|
12
|
Patient Evaluation and Selection in Refractive Surgery. Cornea 2011. [DOI: 10.1016/b978-0-323-06387-6.00166-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
13
|
Artunay O, Yuzbasioglu E, Unal M, Rasier R, Sengul A, Bahcecioglu H. Bimatoprost 0.03% versus brimonidine 0.2% in the prevention of intraocular pressure spike following neodymium:yttrium–aluminum–garnet laser posterior capsulotomy. J Ocul Pharmacol Ther 2010; 26:513-7. [PMID: 20874499 DOI: 10.1089/jop.2009.0146] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
PURPOSE The aim of this study was to compare the efficacy of bimatoprost 0.03% with brimonidine 0.2% in preventing intraocular pressure (IOP) elevations after neodymium:yttrium–aluminum–garnet (Nd:YAG) laser posterior capsulotomy. METHODS In this prospective, randomized, double-masked study, 195 eyes of 195 consecutive patients who had YAG laser capsulotomy for posterior capsule opacification were recruited. Eyes received either 1 drop of bimatoprost 0.03% (98 patients) or brimonidine 0.2% (97 patients) at 1h before laser surgery. A masked observer measured IOP by Goldmann applanation tonometry before treatment and after treatment at 1h, 3h, 24h, and 7 days. Inflammation was evaluated after surgery. Formation of cystoid macular edema was assessed by measuring the macular thickness before and after laser surgery. RESULTS The average peak of postoperative IOP elevation was 2.2±3.9mm Hg in the bimatoprost 0.03% and 3.6±3.1mm Hg in the brimonidine 0.2% group. The difference was statistically significant (P<0.001). Postoperative IOP elevations of 10mm Hg or more occurred in 1 eye (1.56%) in the bimatoprost 0.03% group and 5 eyes (7.35%) in the brimonidine 0.2%. This difference was statistically significant (P<0.001). Macular edema and anterior chamber reaction were not observed related to bimatoprost. No clinically significant side effects were noted in either group. CONCLUSIONS Our results indicate that prophylactic use of bimatoprost 0.03% is more effective than brimonidine 0.2% in preventing IOP elevation immediately after YAG laser capsulotomy. Bimatoprost 0.03% as a prostamide analog may provide new option for preventing IOP elevation after YAG laser capsulotomy.
Collapse
Affiliation(s)
- Ozgur Artunay
- 1 Department of Ophthalmology, Istanbul Bilim University , Istanbul, Turkey
| | | | | | | | | | | |
Collapse
|
14
|
Effectiveness of daily use of brimonidine as antimydriatic agent. J Cataract Refract Surg 2009; 35:1845-6; author reply 1846. [DOI: 10.1016/j.jcrs.2009.06.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2009] [Accepted: 06/08/2009] [Indexed: 11/19/2022]
|
15
|
Current world literature. Curr Opin Ophthalmol 2009; 20:333-41. [PMID: 19535964 DOI: 10.1097/icu.0b013e32832e478f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|